bioLytical Laboratories

bioLytical Laboratories

April 30, 2007 10:00 ET

bioLytical™ Laboratories Recruits Carl Roy as President and CEO

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 30, 2007) - bioLytical™ Laboratories ('bioLytical™') is pleased to announce the appointment of Mr. Carl F. Roy to the position of President and CEO.

bioLytical™ will benefit from Mr. Roy's experience in healthcare and his reputation as a leader who implements change and drives growth. Formerly the President and Chief Executive Officer of Providence Health Care ("Providence") Mr. Roy has comprehensive knowledge of health care systems and the devastating impact of HIV/AIDS. The BC Centre for Excellence in HIV/AIDS, part of Providence's specialty programming, is Canada's largest HIV/AIDS research and treatment program.

"Mr. Roy's extensive network of colleagues in HIV research and development, and his ability to deliver results, will prove invaluable to bioLytical™ as we focus on worldwide commercialization of the INSTI™ HIV-1 Rapid Antibody Test," said Robert Mackie, bioLytical™ Laboratories' founder and Chairman of the board. "Mr. Roy's appointment is representative of the caliber of senior leadership we will continue to attract and recruit."

Mr. Roy comes to bioLytical™ from Perceptronix Medical Inc. ('Perceptronix') where he served as President and Chief Executive Officer from September 2006. Under Mr. Roy's leadership, Perceptronix successfully shifted its strategic focus from research and development to product commercialization.

"After my short but highly successful experience at Perceptronix, I'm excited to be launching another great company into the next phase of its development," said Roy. "I am confident that my expertise in healthcare, facilitation of strategic collaborations and business development will result in the worldwide commercialization of bioLytical™ products. I am particularly pleased to be joining the global effort against HIV/AIDS and advancing the international leadership position so long a feature of British Columbia, thanks to the work of the Centre for Excellence for HIV/AIDS at Providence and bioLytical™."

Mr. Roy has also served as the President of Caritas Health Group in Edmonton and previously, President and Chief Executive Officer of Sudbury General Hospital and St. Joseph's Health Centre in Sudbury, Ontario. Mr. Roy has a Master of Health Science, Administration from the University of Toronto and is a Certified Health Executive (Canadian College of Health Service Executives).

About INSTI™ HIV-1 Rapid Antibody Test

INSTI™ is a highly effective and reliable rapid HIV test that detects the presence of antibodies to HIV in whole blood, serum or plasma in 60 seconds. It has a 99.96% accuracy rate, as demonstrated in extensive clinical trials carried out in multiple centers across Canada. To further ensure INSTI™ maintains its high quality, it is manufactured in Canada under strict controls in a state-of-the-art ISO accredited facility. INSTI has gone through extensive clinical trials and is the only HIV kit approved by Health Canada for Point of care testing.

About bioLytical™ Laboratories (www.biolytical.com)

bioLytical™ Laboratories (Inc.) is a leading developer and manufacturer of diagnostic tests for global health care markets. The company produces the highly accurate and reliable INSTI™ kit; the only rapid HIV test kit approved by Health Canada for use in a point of care setting, such as a doctor's office or hospital. bioLytical™ is a privately owned company with headquarters and state of the art manufacturing facility located in Richmond, British Columbia, with offices in United Kingdom and Uganda, Africa. For more information about bioLytical and INSTI™, please visit www.biolytical.com.

This news release is not, and under no circumstances is to be construed as, an
advertisement, solicitation or offering of securities of bioLytical™ Laboratories. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Contact Information